Lineage Cell Therapeutics Return on Equity

Lineage Cell Therapeutics (LCTX) currently reports a ROE of -53.95%. That is below the Healthcare sector average of 11.15%. Use the charts on this page to explore Lineage Cell Therapeutics's ROE history and peer comparisons.

Lineage Cell Therapeutics's ROE of -53.95% is lower than the Healthcare sector average of 11.15%. That is roughly 583.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Lineage Cell Therapeutics's current -53.95% should be judged against Healthcare norms (sector average: 11.15%) and against LCTX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -53.95%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for Lineage Cell Therapeutics, and consider following LCTX for alerts when major investors trade the stock.

Lineage Cell Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -53.95% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LCTX with unrelated industries.